the product in the database has an inactive status
indications:
Vaccinations against diphtheria, tetanus, pertussis and pertussispolio.
Composition:
0.5 ml (1 dose) contains not less than 30 IU. (25 Lf) diphtheria toxoid, not less than 40 IU. (7 Lf) tetanus toxoid, 40 μg of pertussis toxoid, inactivated poliovirus (Salk), type 1 - 40 units of D antigen, inactivated poliovirus (Salk), type 2 - 8 units of antigen D, inactivated polio virus (Salk), type 3 - 32 units of D antigen.
Action:
Diphtheria vaccine, tetanus, pertussis (acellular) andpolio. Soon after vaccination antibodies are produced against all antigens included in the vaccine. The protective level of antibodies against diphtheria, tetanus and poliomyelitis is reached one to two weeks after the second dose. After the booster dose, protection against diphtheria and tetanus is estimated at approximately 10 years. The protective effect of antibodies against poliomyelitis and pertussis and the need for booster doses has not yet been established.
Contraindications:
Hypersensitivity to the components of the vaccine. Progressive neurological diseases. Post-vaccination reactions: hypotonic-hyporesponsive reactions after previous administration of pertussis vaccine, fever above 40.5 degrees. without an identified cause, uninterrupted crying lasting longer than 3 hours within 48 hours of vaccination, convulsions with or without fever within 3 days after vaccination.
Precautions:
Vaccination should be postponed in the event of an acute febrile illness. In immunocompromised children, a sufficient immune response may not be obtained.
Pregnancy and lactation:
Side effects:
Common: malaise, headache and fever above 38 degrees, tenderness, redness and swelling at the injection site. Rare: irritability and uninterrupted crying, tenderness, redness and swelling above 6 cm at the injection site, eczema and dermatitis. Very rare: high fever above 40 degrees, occasional fever with convulsions, anaphylactic reactions, granuloma or sterile abscess at the injection site, urticaria. The possibility of hypotonic hyporeactive episodes can not be totally ruled out.
Dosage:
Intramuscularly, in special cases deeply subcutaneously (eg haemorrhagic diathesis). The series of primary immunizations, which can be started at the earliest in children of 2 months, consists of two or three doses of 0.5 ml administered 1-2 months apart. The supplementary dose should be administered in 2 years at an interval of at least 6 months from the primary vaccination course.
(C)
